Biomarker Challenges: How to Deal with Lack of Parallelism?

It is widely acknowledged that parallelism should be performed early in the method development process of biomarker ligand-binding assays. This assessment yields substantial information on the performance of an assay, most notably, selectivity, minimal required dilution (MRD) and possible matrix interference. Several publications have already covered the necessity of performing parallelism and how it should be analyzed. However, specific information on how a lack of parallelism should be addressed and ways to remedy the problem is less discussed. During this Rapid Fire presentation, parallelism issues will be studied with a focus on their meaning and ways to improve them. Parallelism results from different methods will be showcased, highlighting how lack of proper parallelism data was interpreted and how such data was improved. This presentation will emphasize the importance of understanding parallelism data to meet current needs in biomarkers assay development.